新引入olaparib的患者中贫血的发展因素:一个回顾性病例控制研究
Chihiro Shiraishi1, Toshinori Hirai1, Michiko Kaneda2
1Department of Pharmacy, Mie University Hospital, Mie, Japan.
Medicine
|July 28, 2023
概括
奥拉巴里布经常导致贫血,通常是宏细胞性,即使没有叶酸或维生素B12缺乏. 在接受olaparib的患者中,先前高剂量的卡博普拉丁和失血症可能会增加贫血风险.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 贫血是olaparib的常见剂量限制性毒性.
- 关于olaparib诱导的贫血的临床特征的数据有限.
- 营养因素,如叶酸和维生素B12在这种毒性中的作用还不清楚.
研究的目的:
- 为了研究olaparib诱导的贫血的临床特征.
- 为了检查叶酸或维生素B12在olaparib引起的贫血中的潜在作用.
- 为了探索olaparib诱导的贫血和之前的碳波拉丁暴露或胃肠道事件之间的关联.
主要方法:
- 对接受olaparib.com的患者进行了回顾性病例控制研究.
- 在olaparib治疗期间发生≥3级贫血的患者的分析.
- 在接受卵巢或子宫内膜癌治疗的患者中评估叶酸和维生素B12水平的子研究.
主要成果:
- 45%的患者患有≥3级贫血,往往需要降低剂量或停止治疗.
- 50%的患有严重贫血的患者表现出宏细胞贫血,经常发生在那些先前接触过碳波拉丁的患者中.
- 在患有贫血的患者中,没有发现叶酸或维生素B12缺乏;然而,失血症更为常见.
结论:
- 奥拉巴里布诱导的贫血通常呈现为宏细胞或常细胞红细胞贫血.
- 贫血是独立于叶酸或维生素B12缺乏而发生的.
- 高累积剂量之前的卡博普拉丁和dysgeusia可能与olaparib诱导的贫血有关.
相关概念视频
01:21Nondisjunction
3.9K
Nondisjunction is the failure of homologous chromosomes or sister chromatids to separate correctly and move to the opposite poles of the cells. This produces daughter cells with abnormal chromosome numbers. Nondisjunction is common during anaphase I or anaphase II of meiosis. Mutations in synaptonemal complex proteins that attach homologous chromosomes increase the chances of nondisjunction in anaphase I of meiosis I. In contrast, mutations in topoisomerases and condensins that hold...
3.9K
01:21Cancer Survival Analysis
386
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
386
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
83
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
83